AmbAgon Therapeutics

AmbAgon Therapeutics

  • Founded: 2020
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: Undisclosed
  • Product link:
  • Funding: $85M A Jan 2022
  • Investors: Nextech Invest, RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, Mission BioCapital, Surveyor Capital

job board

Short description:

Small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins

Drug notes:

6 additional undisclosed programs RD oncology

Long description:

Ambagon Therapeutics is enhancing the activity of tumor suppressors by creating cancer molecule therapeutics. 14-3-3 proteins are adaptor proteins that play a key role in a large number of disease-related pathways, but are intrinsically disordered, making it hard to design small molecule binders. However, these disordered regions become ordered when 14-3-3 binds other “client” protein interactors. Different clients create structurally unique pockets on 14-3-3 enabling Ambagon to develop small molecules that can stabilize specific 14-3–3:client interactions. Ambagon has built an extensive database of 14-3-3:client protein structures to quickly identify the most promising candidates for screening. Amabagon now has five programs in early discovery and expects one to reach development by 2023.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy